p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy

JD Chan; PA Beavis; PK Darcy

Journal article

p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy

JD Chan, PA Beavis, PK Darcy

Cancer Cell | CELL PRESS | Published : 2020

DOI: 10.1016/j.ccell.2020.05.012

Abstract

In this issue of Cancer Cell, Gurusamy et al. use a CRISPR-Cas9 screening approach to demonstrate that deletion of p38 increases multiple phenotypic qualities of effective anti-tumor T cells. Preconditioning T cells with a p38 inhibitor enhances anti-tumor efficacy of adoptive immunotherapy.

University of Melbourne Researchers

Paul Beavis Author

Phillip Darcy Author

Related Projects (2)

TARGETING ADENOSINE MEDIATED IMMUNOSUPPRESSION TO ENHANCE CAR T CELL ACTIVITY IN BREAST CANCER

NEW STRATEGIES FOR ENHANCING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR CANCER

The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet ..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

The authors wish to acknowledge funding support from the National Health and Medical Research Council of Australia, the National Breast Cancer Foundation, Cancer Council of Victoria, and the CLEARbridge Foundation. J.D.C. is supported by a Robert Kirby Award (2020). P.A.B. is supported by a National Breast Cancer Foundation Fellowship (ID#ECF-17-005). P.K.D. is supported by an NHMRC Senior Research Fellowship (APP1136680).